Novavax Stock News

The World Health Organization granted Emergency Use Listing to its COVID-19 vaccine.

The World Health Organization (WHO) has approved the Covovax coronavirus vaccine for emergency use, which is manufactured by the Serum Institute of India under license from the American company Novavax, the WHO said in a statement, Report informs citing R

New Delhi: The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio. This is yet another milestone in our fight against Covid-19. Covovax is now WHO approved for emergency use, showing excellent safety []

The World Health Organisation on Friday approved emergency use listing of Covid vaccine Covovax, produced by the Serum Institute of India under licence from Novavax and part of the Covax facility portfolio.

Today, the WHO approved emergency use listing for Novavax''s vaccine, Covovax. NVAX stock is popping today as a result.

New Delhi, December 17 Serum Institute of India (SII) CEO Adar Poonawalla on Friday hailed WHO''s approval for emergency use of Covovax vaccine for children "as yet another milestone" in the fight against COVID-19. The World Health Organization (WHO) on Friday listed the Covovax as the ninth COVID-19 vaccine for emergency use with an aim to increase the access to vaccination in lower-income countries. It is produced by the Serum Institute of India under the licence from Novavax. Reacting to the development, Poonawalla tweeted, "This is yet another milestone in our fight against COVID-19, Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration…" He tagged Novavax, WHO, Gavi, the Vaccine Alliance, its CEO Seth Berkley and the Gates Foundation. Earlier this week, Poonawalla had said that SII planned to launch Covovax, a COVID-19 vaccine for children in the next six months. He had stated that Covovax which is under trial would offer protection to children all the way down to three years as it had shown excellent data during the trials.

Serum Institute of India''s (SII''s) COVID-19 vaccine Covovax gets approval from the World Health Organisation (WHO) for emergency use. Covovax, COVID-19 Vaccine Produced By Serum Institute of India Under Licence From Novavax, Gets WHO Approval For Emergency Use.

During the last session, Novavax Inc. (NASDAQ:NVAX)s traded shares were 5.51 million, with the beta value of the company hitting 1.25. At the end of the trading day, the stocks price was $194.92, reflecting an intraday gain of 8.60% or $15.43. The 52-week high for the NVAX share is $331.68, that puts it down -70.16 What Will Novavax Inc. (NASDAQ: NVAX) Be Like After It Jumps -70.16% From Its Highs? Read More »

All of these vaccine stocks benefited from rising concerns about the Omicron variant.

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period), of the important January 11, 2022 lead plaintiff deadline .

The protein-based vaccine by Novavax in June was shown to be more than 90% effective, including against a variety of concerning coronavirus variants, in a large, late-stage U.S. trial. Novavax''s shot received its first authorization in Indonesia last month and is awaiting approval in Japan, where it would be manufactured and distributed by Takeda Pharmaceutical.

The European Medicines Agency could approve the Novavax coronavirus vaccine as early as next week, paving the way for emergency use listing from the World Health Organization, the Financial Times reported on Thursday, citing sources.